It was reported that a selective chemical inhibitor of EZH2 could block H3K27 methylation and kill mutant lymphoma cells38, which suggests that cancer may be treated by targeting EZH2 as a therapeutic strategy. This evidence concerns the gene EZH2 and lymphoma.